These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2259226)

  • 21. Intensive treatment of acute leukemia in adults 70 years of age and older.
    Walters RS; Kantarjian HM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
    Cancer; 1987 Jul; 60(2):149-55. PubMed ID: 3474052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
    Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
    de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J
    Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Varying intensity of postremission therapy in acute myeloid leukemia.
    Cassileth PA; Lynch E; Hines JD; Oken MM; Mazza JJ; Bennett JM; McGlave PB; Edelstein M; Harrington DP; O'Connell MJ
    Blood; 1992 Apr; 79(8):1924-30. PubMed ID: 1562720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
    Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R
    Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
    Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
    J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
    Peters WG; Willemze R; Colly LP
    Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
    Rees JK; Gray RG; Swirsky D; Hayhoe FG
    Lancet; 1986 Nov; 2(8518):1236-41. PubMed ID: 2878130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
    Wiernik PH; Glidewell OJ; Hoagland HC; Brunner KW; Spurr CL; Cuttner J; Silver RT; Carey RW; DelDuca V; Kung FH; Holland JF
    Med Pediatr Oncol; 1979; 6(3):261-77. PubMed ID: 381887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive chemotherapy for acute myelogenous leukemia.
    Gale RP; Foon KA; Cline MJ; Zighelboim J
    Ann Intern Med; 1981 Jun; 94(6):753-7. PubMed ID: 6940466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of acute myelocytic leukemia with a daunorubicin-cytarabine-6 thioguanine regimen without maintenance therapy.
    Freund M; Poliwoda H; Bodenstein H; Eisert R
    Onkologie; 1985 Jun; 8(3):150-2. PubMed ID: 3895097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.
    Zittoun R; Jehn U; Fière D; Haanen C; Löwenberg B; Willemze R; Abels J; Bury J; Peetermans M; Hayat M
    Blood; 1989 Mar; 73(4):896-906. PubMed ID: 2645950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.
    Oberg G; Killander A; Björeman M; Gahrton G; Grimfors G; Gruber A; Hast R; Lerner R; Liliemark J; Mattson S; Paul C; Simonsson B; Stalfelt AM; Stenke L; Tidefelt U; Udén AM; Björkholm M;
    Eur J Haematol; 2002 Jun; 68(6):376-81. PubMed ID: 12225396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.